1 års afkast (CAGR)
-0.48%
Bavarian Nordic Exchange (CO, DKK)
BAVA.CO
230.00
+6.80 (+3.05%)
HealthcareBiotechnology
Loading...
3 års afkast (CAGR)
14.36%
5 års afkast (CAGR)
-6.62%
10 års afkast (CAGR)
4.60%
Adobe 2026 Q3 – Er det stemningen, der driver prisen?
Læs mereMarkedsværdi
17.31B
Pris/omsætning
2.75
Ent værdi
18.04B
Pris/bog
1.31
Udbytte afkast
0.00%
Vekst år
-
Udbyttevækst
-
FCF-udbetaling
0.00%
Efterfølgende P/E
11.22
PEG
-
Fremtidig P/E
21.86
EPS-vekst
27.98%
Oplysninger om aktier
Hvad er en børs? Drift, aktører, eksempler
Læs mereAktiediagram
Loading...
Aktiekurs-data
| Åbning | 232.20 |
| Daglig høj | 235.80 |
| Daglig lav | 228.40 |
| Daglig volumen | 375K |
| Højeste gennem alle tider | 401.70 |
| 1 års analytiker estimat | 276.25 |
| Beta | 0.97 |
| EPS (TTM) | 20.31 |
| Udbytte pr. aktie | 0.00 |
| Ex-div dato | - |
| Næste dato for resultatpræsentation | 12 Mar 2026 |
Nedsidepotensial
Loading...
Nedsidepotensial-data
| BAVA.CO | S&P500 | |
| Nuværende prisfald fra top notering | -42.74% | -0.66% |
| Højeste prisfald | -91.83% | -56.47% |
| Højeste efterår dato | 30 Sep 2002 | 9 Mar 2009 |
| Gennemsnitlig fald fra toppen | -48.27% | -10.67% |
| Gennemsnitlig tid til nyt højdepunkt | 101 days | 12 days |
| Maks. tid til nyt højdepunkt | 1935 days | 1805 days |
Nyheder
Bavarian Nordic has put in a strong three year share price run, while fresh optimism around its vaccines business has sharpened the focus on what the current valuation implies about the cash the compa...
9. oktober 2026
Investing.com -- Bavarian Nordic raised its full-year 2026 guidance again on Thursday, lifting its revenue and profitability outlook on stronger-than-expected sales in its Travel Health business. The ...
8. oktober 2026
Revenue and EBITDA margin expectations increased, driven by stronger-than-expected Travel Health sales COPENHAGEN, Denmark, October 8, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced an upgrade...
8. oktober 2026
COPENHAGEN, Denmark, October 5, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on September 1, 2026, under which the Company will repurchase sh...
5. oktober 2026
The Danish biotech sharpened its global vaccine ambitions by tapping Tarja Stenvall, a Big Pharma vet, to take the helm.
28. september 2026
COPENHAGEN, Denmark, September 22, 2026 - Pursuant to Section 31 of the Danish Capital Markets Act, it is hereby announced that as of September 21, 2026, Bavarian Nordic’s holding of treasury shares a...
22. september 2026
COPENHAGEN, Denmark, September 17, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced that Tarja Stenvall has been appointed President and Chief Executive Officer, effective October 15, 2026, succ...
17. september 2026
COPENHAGEN, Denmark, September 4, 2026 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Company's share capital has been increased by nominally DKK 285,900 as a consequence of employees’ exe...
4. september 2026